Jump to ContentJump to Main Navigation

Open Medicine

formerly Central European Journal of Medicine

1 Issue per year

IMPACT FACTOR 2014: 0.153
5-year IMPACT FACTOR: 0.183

SCImago Journal Rank (SJR) 2014: 0.135
Source Normalized Impact per Paper (SNIP) 2014: 0.124
Impact per Publication (IPP) 2014: 0.193

Open Access


Complicated course of facial cellulitis caused by Staphylococcus aureus in a 13-year-old boy with neutropenia — an adverse event analysis

1Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Bujwida 44, 50-345, Wroclaw, Poland

2Department of Forensic Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 4, 50-345, Wroclaw, Poland

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. (CC BY-NC-ND 3.0)

Citation Information: Open Medicine. Volume 8, Issue 2, Pages 220–224, ISSN (Online) 2391-5463, DOI: 10.2478/s11536-012-0106-9, January 2013

Publication History

Published Online:


Keywords: Cellulitis; Neutropenia; Adverse event; Management; Staphylococci

  • [1] Krasagakis K., Valachis A., Maniatakis P., Krüger-Krasagakis S., Samonis G., Tosca A.D., Analysis of epidemiology, clinical features and management of erysipelas, Int. J. Dermatol., 2010, 49, 1012–1017 http://dx.doi.org/10.1111/j.1365-4632.2010.04464.x [Web of Science] [CrossRef]

  • [2] Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al., Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin. Infect. Dis., 2005, 41, 1373–1406 http://dx.doi.org/10.1086/497143 [CrossRef]

  • [3] Celestin R., Brown J., Kihiczak G., Schwartz R.A., Erysipelas: a common potentially dangerous infection, Acta Dermatovenerol. Alp. Panonica. Adriat., 2007, 16, 123

  • [4] Bartholomeeusen S., Vandenbroucke J., Truyers C., Buntinx F., Epidemiology and comorbidity of erysipelas in primary care, Dermatology., 2007, 215, 118–122 http://dx.doi.org/10.1159/000104262 [CrossRef] [Web of Science]

  • [5] Jorup-Rönström C., Epidemiological, bacteriological and complicating features of erysipelas, Scand. J. Infect. Dis., 1986, 18, 519–524 http://dx.doi.org/10.3109/00365548609021656 [CrossRef]

  • [6] Lazzarini L., Conti E., Tositti G., de Lalla F., Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital, J. Infect. 2005, 51, 383–389 http://dx.doi.org/10.1016/j.jinf.2004.12.010 [CrossRef]

  • [7] Krasagakis K., Samonis G., Maniatakis P., Georgala S., Tosca A., Bullous erysipelas: clinical presentation, staphylococcal involvement and methicillin resistance, Dermatology., 2006, 212, 31 http://dx.doi.org/10.1159/000089019 [CrossRef]

  • [8] Müller-Lühr M., Breyer N., Martin A., Haacke H., Erysipelas in neutropenia of unknown origin, successfully treated with r-metHuG-CSF (filgrastim), Ann. Hematol., 1994, 69, 97–98 http://dx.doi.org/10.1007/BF01698490 [CrossRef]

  • [9] Leclerc S., Teixeira A., Mahé E., Descamps V., Crickx B., Chosidow O., Recurrent erysipelas: 47cases, Dermatology., 2007, 214, 52–57 http://dx.doi.org/10.1159/000096913 [Web of Science]

  • [10] Bartholomeeusen S., Vandenbroucke J., Truyers C., Buntinx F., Epidemiology and comorbidity of erysipelas in primary care, Dermatology., 2007, 215, 118–122 http://dx.doi.org/10.1159/000104262 [CrossRef] [Web of Science]

  • [11] Krasagakis K., Samonis G., Valachis A., Maniatakis P., Evangelou G., Tosca A., Local complications of erysipelas: a study of associated risk factors, Clin. Exp. Dermatol., 2011, 36, 351–354 http://dx.doi.org/10.1111/j.1365-2230.2010.03978.x [CrossRef]

  • [12] Wolfson J.S., Sober A.J., Rubin R.H., Dermatologic manifestations of infections in immunocompromised patients, Medicine (Baltimore)., 1985, 64, 115–133

  • [13] Glauser M., Empiric therapy of bacterial infections in patients with severe neutropenia., Diagn. Microbiol. Infect. Dis., 1998, 31, 467–472 http://dx.doi.org/10.1016/S0732-8893(98)00038-8 [CrossRef]

  • [14] Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al., 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clin. Infect. Dis., 2002, 34, 730–751 http://dx.doi.org/10.1086/339215 [CrossRef]

  • [15] Institute of Medicine: To err is human: building a safer health system. National Academy Press, Washington, 2000

  • [16] Schito G.C., Debbia E.A., Pesce A., Susceptibility of respiratory strains of Staphylococcus aureus to fifteen antibiotics: results of a collaborative surveillance study (1992–1993). The Alexander Project Collaborative Group, J. Antimicrob. Chemother., 1996, 38, 97–106 http://dx.doi.org/10.1093/jac/38.suppl_A.97 [CrossRef]

  • [17] Talan D.A., Krishnadasan A., Gorwitz R.J., Fosheim G.E., Limbago B., Albrecht V., et al., EMERGEncy ID Net Study Group, Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008, Clin. Infect. Dis. 2011, 53, 144–149 http://dx.doi.org/10.1093/cid/cir308 [CrossRef]

  • [18] Jones M.E., Karlowsky J.A., Draghi D.C., Thornsberry C., Sahm D.F., Nathwani D., Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy, Int. J. Antimicrob. Agents., 2003, 22, 406–419 http://dx.doi.org/10.1016/S0924-8579(03)00154-7 [CrossRef]

  • [19] Sader H.S., Flamm R.K., Farrell D.J., Jones R.N., Activity Analyses of Staphylococcal Isolates From Pediatric, Adult, and Elderly Patients: AWARE Ceftaroline Surveillance Program, Clin. Infect. Dis., 2012, 55, 181–186 http://dx.doi.org/10.1093/cid/cis560 [Web of Science] [CrossRef]

  • [20] Deotale V., Mendiratta D.K., Raut U., Narang P., Inducible clindamycin resistance in Staphylococcus aureus isolated from clinical samples. Indian J. Med. Microbiol., 2010, 28, 124–126 http://dx.doi.org/10.4103/0255-0857.62488 [Web of Science] [CrossRef]

  • [21] Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al., Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities, N. Engl. J. Med., 2005, 352, 1436–1444 http://dx.doi.org/10.1056/NEJMoa043252 [CrossRef]

  • [22] Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al., EMERGEncy ID Net Study Group, Methicillin resistant S. aureus infections among patients in the emergency department, N. Engl. J. Med., 2006, 355, 666–674 http://dx.doi.org/10.1056/NEJMoa055356 [CrossRef]

  • [23] Morgan M., Treatment of MRSA soft tissue infections: an overview, Injury., 2011, 42 Suppl 5, 11–17 http://dx.doi.org/10.1016/S0020-1383(11)70127-9 [CrossRef]

  • [24] Shimizu. T, Tokuda Y., Necrotizing fasciitis, Intern. Med., 2010, 49, 1051–1057 http://dx.doi.org/10.2169/internalmedicine.49.2964 [Web of Science] [CrossRef]

Comments (0)

Please log in or register to comment.